{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Ipamorelin",
    "short_name": "Ipamorelin",
    "aliases": [
      "IPA"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what Ipamorelin is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Not FDA-approved. Human use is widely reported in gray-market contexts. Product identity, purity, and dosing consistency are uncertain outside regulated manufacturing."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Primary risks relate to GH/IGF-1 axis perturbation, metabolic effects (e.g., glucose/insulin signaling), appetite changes, fluid retention, and unknown long-term outcomes in non-medical use. Evidence is limited by heterogeneous study designs and uncertain real-world product quality.",
      "developmental_systems_of_concern": [
        "gh_igf",
        "metabolic",
        "puberty"
      ],
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Ipamorelin is a synthetic GHRP-class peptide studied for short-term effects on GH release and downstream endocrine/metabolic signaling. Clinical evidence for meaningful health outcomes is limited; many claims rely on mechanism and small studies rather than robust trials.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a synthetic GHRP-class peptide studied for short-term effects on GH release and downstream endocrine/metabolic signaling",
        "weight-loss support (commonly discussed)",
        "metabolic health support (anecdotal)",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      },
      {
        "id": "E2",
        "title": "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.",
        "source_type": "journal_article",
        "source_id": "PMID:41490200",
        "evidence_grade": "human_interventional",
        "year": 2026,
        "url": "https://pubmed.ncbi.nlm.nih.gov/41490200/",
        "notes": "Use to bound claims; does not establish broad clinical benefit."
      },
      {
        "id": "E3",
        "title": "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.",
        "source_type": "review",
        "source_id": "PMID:41476424",
        "evidence_grade": "unknown",
        "year": 2026,
        "url": "https://pubmed.ncbi.nlm.nih.gov/41476424/",
        "notes": "Safety framing; not a protocol guide."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Ipamorelin",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-19T16:33:35.011906+00:00",
        "change_type": "content_update",
        "summary": "Filled ipamorelin core fields and linked conservative evidence refs (no instructions).",
        "detail": "Removed Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon. language from key descriptive fields and ensured overview evidence_refs are present. Evidence entries are intentionally conservative scaffolds and will be finalized with specific PMIDs/years in a batch pass.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      },
      {
        "date": "2026-01-19T16:47:29.891984+00:00",
        "change_type": "content_update",
        "summary": "Curation update: section structure standardized; content review pending. No protocols or instructions are provided.",
        "detail": "Auto-filled evidence metadata using NCBI E-utilities (query-based). Best-effort year extraction for non-NCBI pages where applicable. No dosing/protocol instructions added.",
        "evidence_refs": []
      }
    ],
    "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
    "meta": {
      "appears_in_blends": [
        "cjc-ipamorelin"
      ]
    },
    "topics": {
      "primary": [
        "topic_muscle_recovery",
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "ipamorelin"
  },
  "canonical_name": "Ipamorelin",
  "interactions": {
    "drug_classes": [
      "endocrine-axis-modulation-context"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "Ipamorelin is a growth-hormone secretagogue discussed for recovery, sleep, and body composition goals. It can affect appetite, fluid balance, and glucose regulation.",
    "benefits": [
      "recovery and sleep-quality discussions in training communities (subjective reports vary)",
      "body composition interest tied to GH/IGF-1 signaling (outcomes vary)",
      "often mentioned as a “milder” GH secretagogue compared with older options"
    ],
    "side_effects_common": [
      "increased appetite",
      "water retention or puffiness",
      "headache or lethargy"
    ],
    "side_effects_serious": [
      "worsening glucose control in susceptible users",
      "severe swelling, shortness of breath, or chest pain"
    ],
    "who_should_be_cautious": [
      "people with diabetes, prediabetes, or unstable blood sugar",
      "people with untreated sleep apnea (GH axis and fluid shifts can matter)",
      "pregnant or breastfeeding individuals",
      "adolescents (endocrine-axis impact plus limited non-medical context)"
    ],
    "schema_version": "practical_block_v1"
  }
}
